Clinical Research Directory

Inclusion Criteria: * Previously-untreated AML (≥ 20% blasts in bone marrow and/or peripheral blood) * Age of 15 years or older, 60 years or younger * Adequate performance status (Karnofsky score of 50 or more) * Adequate hepatic and renal function (AST, ALT, and bilirubin \< 2.5 x upper normal limit and creatinine \< 2.0 mg/dL \& creatinine clearance ≥ 50 mL/min). Elevation of AST or ALT due to hepatic infiltration of leukemic cells will be permitted. * Adequate cardiac function (left ventricular ejection fraction ≥45% on heart scan or echocardiogram) * Signed informed consent Exclusion Criteria: * Patients with history of chemotherapy for leukemia or cytarabine and anthracycline treatment for any malignancy. Hydroxyurea for reduction of leukemic cell burden before induction chemotherapy will be permitted. * Patients with acute promyelocytic leukemia * Patients with blast crisis of chronic myeloid leukemia * Patients with central nervous system (CNS) leukemia or granulocytic sarcoma without bone marrow involvement * Presence of uncontrolled and/or severe medical condition (infection, bleeding, cardiovascular disease including myocardial infarction within previous 6 months.) * Nursing women, pregnant women, women of childbearing potential who do not want adequate contraception * Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years following therapy with curative intent (except curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia)